ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AGIO vs VERA // FREE CASH FLOW YIELD

Agios Pharmaceuticals Inc. (NASDAQ) VS. Vera Therapeutics Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: AGIO 3 — VERA 2
▲ FREE CASH FLOW YIELD LEADER: VERA
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGIO VS. VERA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AGIO VERA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -33.80% -35.00% +1.20 AGIO /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -16.97% -10.99% -5.98 VERA /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 48.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 11.84 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 AGIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.2 52.8 -15.57 VERA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.22B $2.20B $22.6M AGIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AGIO REV VERA REV AGIO GROSS % VERA GROSS % AGIO FCF VERA FCF
FY 2025 $54.0M $0 88.3% — -$377.3M -$241.7M
FY 2024 $36.5M $0 88.6% — -$391.5M -$135.7M
FY 2023 $26.8M $0 — — -$296.1M -$92.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGIO // BETA —
VERA // BETA —